Immortalization of Mesenchymal Stem Cells for Application in Regenerative Medicine and Their Potential Risks of Tumorigenesis
Yamaguchi N., Horio E., Sonoda J., Yamagishi M., Miyakawa S., Murakami F.
Clinical Trial on Scar, Immune Modulation, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Int J Mol Sci (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39769322
- PMCID
- PMC11676347
- DOI
- 10.3390/ijms252413562
- Citations
- 18
Abstract (original English)
Regenerative medicine utilizes stem cells to repair damaged tissues by replacing them with their differentiated cells and activating the body's inherent regenerative abilities. Mesenchymal stem cells (MSCs) are adult stem cells that possess tissue repair and regenerative capabilities and immunomodulatory properties with a much lower risk of tumorigenicity, making them a focus of numerous clinical trials worldwide. MSCs primarily exert their therapeutic effects through paracrine effects via secreted factors, such as cytokines and exosomes. This has led to increasing interest in cell-free therapy, where only the conditioned medium (also called secretome) from MSC cultures is used for regenerative applications. However, MSCs face certain limitations, including cellular senescence, scarcity, donor heterogeneity, complexity, short survival post-implantation, and regulatory and ethics hurdles. To address these challenges, various types of immortalized MSCs (ImMSCs) capable of indefinite expansion have been developed. These cells offer significant promise and essential tools as a reliable source for both cell-based and cell-free therapies with the aim of translating them into practical medicine. However, the process of immortalization, often involving the transduction of immortalizing genes, poses potential risks of genetic instability and resultant malignant transformation. Cell-free
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level AMeta-analysisPubMed
Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis.
Meta-analysis with a reported sample of 323 on Scar, published in Eur J Obstet Gynecol Reprod Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 323
Eur J Obstet Gynecol Reprod Biol - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol - Level AMeta-analysisPubMed
Efficacy and safety of autologous cell-based therapies for atrophic acne scar treatment: an updated systematic review and meta-analysis with in-depth methodological and clinical insights.
Meta-analysis with a reported sample of 500 on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 500
Front Cell Dev Biol - Level ASystematic ReviewEurope PMC
Comparative Efficacy and Safety of Fractional CO<sub>2</sub> Laser and Gold Microneedling Radiofrequency for Atrophic Acne Scars: A Systematic Review
Systematic Review on Chronic Wound, Scar, published in Skin Res Technol (2026) — summary generated from the PubMed abstract.
- 2026
Skin Res Technol - Level AMeta-analysisPubMed
Role of exosome therapy in reconstructive surgery: a review.
Meta-analysis on Chronic Wound, Scar, Immune Modulation, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Med (Lausanne)1 citations